Stephens Investment Management Group LLC Grows Position in BioLife Solutions, Inc. (NASDAQ:BLFS)

Stephens Investment Management Group LLC lifted its position in BioLife Solutions, Inc. (NASDAQ:BLFS - Free Report) by 16.7% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 495,970 shares of the medical equipment provider's stock after buying an additional 70,875 shares during the period. Stephens Investment Management Group LLC owned approximately 1.07% of BioLife Solutions worth $12,875,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. State Street Corp grew its position in shares of BioLife Solutions by 7.3% in the 3rd quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider's stock worth $35,364,000 after buying an additional 95,788 shares during the last quarter. Geode Capital Management LLC grew its position in BioLife Solutions by 2.2% during the 3rd quarter. Geode Capital Management LLC now owns 842,771 shares of the medical equipment provider's stock worth $21,107,000 after purchasing an additional 18,473 shares during the last quarter. Rockefeller Capital Management L.P. grew its position in BioLife Solutions by 81.3% during the 3rd quarter. Rockefeller Capital Management L.P. now owns 585,497 shares of the medical equipment provider's stock worth $14,661,000 after purchasing an additional 262,504 shares during the last quarter. Curi RMB Capital LLC grew its position in BioLife Solutions by 0.5% during the 3rd quarter. Curi RMB Capital LLC now owns 421,933 shares of the medical equipment provider's stock worth $10,565,000 after purchasing an additional 2,283 shares during the last quarter. Finally, Eagle Asset Management Inc. grew its position in BioLife Solutions by 2.9% during the 3rd quarter. Eagle Asset Management Inc. now owns 352,897 shares of the medical equipment provider's stock worth $9,221,000 after purchasing an additional 10,091 shares during the last quarter. Hedge funds and other institutional investors own 93.24% of the company's stock.

BioLife Solutions Stock Performance

NASDAQ BLFS traded up $0.80 on Thursday, hitting $27.14. 244,329 shares of the company's stock traded hands, compared to its average volume of 234,656. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03. BioLife Solutions, Inc. has a 1-year low of $14.50 and a 1-year high of $29.55. The firm's 50-day moving average price is $26.78 and its two-hundred day moving average price is $25.29. The firm has a market capitalization of $1.26 billion, a PE ratio of -25.60 and a beta of 1.91.

Analysts Set New Price Targets

Several analysts have weighed in on BLFS shares. HC Wainwright dropped their target price on shares of BioLife Solutions from $29.00 to $27.00 and set a "buy" rating on the stock in a research report on Monday, November 18th. TD Cowen boosted their target price on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock a "buy" rating in a research report on Wednesday, November 13th. Northland Securities boosted their target price on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock an "outperform" rating in a research report on Wednesday, January 8th. KeyCorp boosted their target price on shares of BioLife Solutions from $30.00 to $33.00 and gave the stock an "overweight" rating in a research report on Friday, December 13th. Finally, Craig Hallum boosted their target price on shares of BioLife Solutions from $30.00 to $32.00 and gave the stock a "buy" rating in a research report on Wednesday, November 13th. One analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, BioLife Solutions presently has an average rating of "Moderate Buy" and an average price target of $29.43.

Insider Activity at BioLife Solutions

In related news, EVP Aby J. Mathew sold 7,604 shares of the business's stock in a transaction on Monday, December 16th. The shares were sold at an average price of $27.33, for a total value of $207,817.32. Following the completion of the transaction, the executive vice president now directly owns 276,315 shares in the company, valued at $7,551,688.95. The trade was a 2.68 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Troy Wichterman sold 987 shares of the business's stock in a transaction on Monday, January 6th. The shares were sold at an average price of $27.02, for a total transaction of $26,668.74. Following the completion of the transaction, the chief financial officer now owns 121,779 shares of the company's stock, valued at approximately $3,290,468.58. This represents a 0.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 53,851 shares of company stock worth $1,188,762 in the last three months. Company insiders own 2.20% of the company's stock.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.